Abstract 26P
Background
Gasotransmitters have been established as key players in cancer pathophysiology including breast cancer (BC). Hydrogen sulfide (H2S), being the newest member of gasotransmitters family, was found to be highly elevated in BC tissues. Cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3MST) are the endogenous producers of H2S in viable cells. High expression of CBS and CSE in BC tissues was noticed. However, 3MST received less attention. Thus, the aim of this work is to unravel the expression pattern and regulation of 3MST in BC patients and cell lines.
Methods
BC female patients (n=20) were recruited. Patients’ clinical features showed that 65% of patients had lymph node metastasis, 15% were in stage 3-4 of BC, 25% had tumor size ≥5 cm, and 45% were in premenopausal status. Total RNA was extracted using Biazol, reverse transcribed and quantified using qRT-PCR. Western blot analysis was used to quantify the protein. In-silico analysis was used to identify microRNAs (miRNAs) targeting 3MST. MDA-MB-231 cells were cultured and transfected using oligonucleotides. H2S levels were measured by fluorescence probe (AzMc). Functional analysis experiments such as trans-well migration, MTT and colony forming assays were performed in MDA-MB-231 cells following ectopic miR-548 expression.
Results
3MST was found to be significantly up-regulated in BC tissues compared to the non-cancerous tissues. Significant high expression for 3MST was correlated to tumor size ≥5 cm, albeit not to lymph node metastasis nor to menopause. MiR-548 was listed among the top potential regulators of 3MST using 6 different bioinformatics softwares. Ectopic expression of miR-548 in MDA-MB-231 cells resulted in a marked repression of 3MST on both mRNA and protein levels. H2S levels were significantly repressed by 3MST siRNAs and miR-548 mimics. On the functional level, miR-548 markedly reduced cellular viability, migration and colony forming ability of MDA-MB-231 cells.
Conclusions
This study sheds light onto the significant involvement of 3MST in H2S signaling and its positive correlation with BC aggressiveness. Moreover, it highlights its potential target-ability using miR-548 as a novel tumor suppressor therapeutic approach in BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Swiss National Science Foundation (SNSF), grant SNF IZSTZ0_198887.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74P - Tumor agnostic comparison of immunohistochemistry and next-generation sequencing in detecting ALK fusions and assessment of ALK tyrosine kinase inhibitor efficacy
Presenter: Monica Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Target identification by TIME phenotypes
Presenter: Robert Seitz
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Prediction of response to palliative chemotherapy by circulating tumor DNA (ctDNA) kinetics in metastatic pancreatic cancer
Presenter: Patrick Kirchweger
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - High resolution in situ analysis reveals phenotypic and functional diversification within single pancreatic tumour ducts
Presenter: Ellis Michiels
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Implementing genomic profiling as standard-of-care for glioblastoma patients
Presenter: Vincent Fougner
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Cyclic fasting-mimicking diet as a strategy to improve the efficacy of standard antitumor therapies in cancer patients
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of response-predictive biomarkers for lisavanbulin: A phase II study in patients with recurrent glioblastoma
Presenter: Juanita Lopez
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Racial disparities in phase I lung cancer clinical trials
Presenter: Rohit Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
Presenter: Antoine Mavrikios
Session: Cocktail & Poster Display session
Resources:
Abstract